The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nivolumab plus ipilimumab (N+I) in patients (pts) with colorectal cancer (CRC) with BRCA1/2 alterations (alts): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.
 
Olatunji Alese
Employment - Emory University
Consulting or Advisory Role - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Civala; CUE Biopharma; Exelixis; Ipsen; Loxo/Lilly; Revolution Medicines; Taiho Oncology; Takeda
Research Funding - Arcus Biosciences (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); GlaxoSmithKline (Inst); InhibRx (Inst); Ipsen (Inst); Taiho Pharmaceutical (Inst)
Other Relationship - COMPASS THERAPEUTICS, INC
 
Michael Rothe
No Relationships to Disclose
 
Elizabeth Garrett-Mayer
No Relationships to Disclose
 
Carolyn Carrera
No Relationships to Disclose
 
Evan Pisick
No Relationships to Disclose
 
Timothy Cannon
Honoraria - AstraZeneca; Revolution Medicines
 
Justin Moyers
Consulting or Advisory Role - OncLive/MJH Life Sciences; Pfizer; Replimune
Speakers' Bureau - Curio Science
 
Mehmet Akce
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Curio Science; Curio Science; Daiichi Sankyo, Inc.; Dava Oncology; Eisai; Eisai; Eisai; Eisai; Eisai; Exelixis; Genentech; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; IDEOlogy Health; Incyte; Ipsen; Isofol Medical; MDoutlook; OncLive/MJH Life Sciences; Partner Therapeutics; QED Therapeutics; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Eisai (Inst); Genentech (Inst); IMPAC Medical Systems (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); ProDa (Inst); RedHill Biopharma (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst); Xencor (Inst)
 
Jimmy Hwang
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Caris Centers of Excellence; GlaxoSmithKline; Ipsen; Jazz Pharmaceuticals
 
Mridula Krishnan
No Relationships to Disclose
 
Ankoor Biswas
No Relationships to Disclose
 
Majd Chahin
No Relationships to Disclose
 
Meredith McKean
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Daiichi Sankyo (Inst); IDEAYA Biosciences (Inst); IQvia (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Pierre Fabre (Inst); Regeneron (Inst); Revolution Medicines (Inst)
Research Funding - Arcus Biosciences (Inst); Aulos Bioscience (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Erasca, Inc (Inst); GenVivo (Inst); Gilead Sciences (Inst); IDEAYA Biosciences (Inst); Ikena Oncology (Inst); immatics (Inst); Immunocore (Inst); Iovance Biotherapeutics (Inst); Jazz Pharmaceuticals (Inst); Kezar Life Sciences (Inst); Krystal Biotech (Inst); Merck (Inst); Moderna Therapeutics (Inst); Nested Therapeutics (Inst); Novartis (Inst); NucMito Pharmaceuticals (Inst); OncoC4 (Inst); Pfizer (Inst); Pierre Fabre (Inst); Prelude Therapeutics (Inst); Regeneron (Inst); Repimune (Inst); Sapience Therapeutics (Inst); Synthorx (Inst); Teva (Inst); TScan Therapeutics (Inst)
 
Davendra Sohal
Consulting or Advisory Role - AADi; AstraZeneca/MedImmune; Bayer; Elevar Therapeutics; Regeneron; Totus Medicines; TransThera Sciences (Nanjing), Inc.; Valar Labs
Speakers' Bureau - AstraZeneca; Incyte; Seagen
Research Funding - Ability Pharma (Inst); Amgen (Inst); Apexigen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bexion (Inst); Bristol-Myers Squibb (Inst); FibroGen (Inst); Genentech (Inst); Hengrui Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); NextCure (Inst); Regeneron (Inst); Replimune (Inst); Roche (Inst); Triumvira Immunologics, Inc (Inst)
Travel, Accommodations, Expenses - Ability Pharma
 
Tilak Sundaresan
No Relationships to Disclose
 
Uma Suryadevara
No Relationships to Disclose
 
Muhammad Usman
No Relationships to Disclose
 
Abigail Gregory
Employment - Pfizer (I)
Stock and Other Ownership Interests - Biohaven Pharmaceuticals (I); Pfizer (I)
Travel, Accommodations, Expenses - Pfizer (I)
 
Susan Halabi
Employment - ASCO
Consulting or Advisory Role - BeiGene; Bristol-Myers Squibb; CG Oncology; J&J; Sanofi
 
Richard Schilsky
Leadership - Clarified Precision Medicine; Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Honoraria - Abbvie; Toray Industries; WUGEN, Inc.
Consulting or Advisory Role - Cellworks; Sygnomics; Veracyte; Zephyr AI
Research Funding - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst); Taiho Oncology (Inst)